

Corporate Presentation

October 2020

Forward Looking Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects", "plans", "believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause TG Therapeutics' actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, drug development, and commercialization and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and TG Therapeutics undertakes no obligation to update these statements, except as required by law. statements, except as required by law.



Fearless Pursuit

- Founded 8 years ago with one goal in mind... to create the best possible treatment options for patients with B-Cell diseases
- Focused on cancer & autoimmune disease with registration programs ongoing in:
 - Chronic Lymphocytic Leukemia (CLL)
 - Marginal Zone Lymphoma (MZL)
 - Follicular Lymphoma (FL)
 - Multiple Sclerosis (MS)



B-Cell Focused Platform Clinical Stage Portfolio Overview

Drug Candidate	Mechanism of Action	Stage of Development	
Umbralisib (TGR-1202)	ΡΙ3Κδ/ϹΚ1ε	Phase 3	
Ublituximab (TG-1101)	Anti-CD20	Phase 3	
Cosibelimab (TG-1501)	Anti-PD-L1	Phase 1b	
TG-1701	BTKi	Phase 1	
TG-1801	Anti-CD47/CD19	Phase 1	

2020: Transformational Year w/ Multiple Pivotal Data Sets

UNITY-NHL Rel/Ref MZL and FL

– Umbralisib Monotherapy –

Positive Topline ORR Data

ODD Granted for MZL & FL and BTD granted for MZL

Rolling NDA Submission accepted by the US FDA August 2020 UNITY-CLL Front Line & Rel/Ref

– Umbralisib + Ublituximab (U2) –

Trial Conduced Under SPA

Enrolled ~420 patients

Positive topline results announced May 2020

ULTIMATE I & II Relapsing MS

– Ublituximab Monotherapy –

Trials Conducted under SPA

Enrolled Over 1100 Patients

Awaiting topline results, Target 4Q 2020

• Potential for FDA Approvals in MZL, FL, CLL, SLL and MS from 2020 to 2022

• Commercial Preparations Underway



Umbralisib:

Investigational dual PI3k-delta & CK1-epsilon inhibitor



- Demonstrated activity across NHL and CLL
- Potentially differentiated tolerability profile over 1st generation compounds
- Once daily v. twice daily for 1st generation compounds



UNITY-NHL - *Umbralisib Monotherapy Cohorts Relapsed/Refractory MZL* & *FL*

- MZL & FL Cohort's Met Primary End Point of Overall Response Rate (ORR)
 - Exceeding 40% ORR hurdle
 - Interim efficacy analysis of MZL cohort, n=42, showed 52% ORR, including 19% Complete Response (CR) rate
- Umbralisib monotherapy appeared to be well tolerated in both cohorts, with a safety profile consistent with previous reports
- Rolling NDA submission for umbralisib to treat R/R MZL and FL accepted by the US FDA August 2020
 - MZL PDUFA goal date of February 15, 2021
 - FL PDUFA goal date of June 15, 2021
- Targeting presentation of full data by year-end 2020


UNITY-NHL Ph2b Trial FL & MZL Cohorts

> Umbralisib (TGR-1202) Monotherapy

Positive Topline ORR Results						
Target ORR Achieved	>40%					
Enrollment Complete MZL (n=69) FL (n=118)	Aug 2018 Oct 2018					
Targeting Full Data Presentation	YE 2020					



MZL and FL are chronic and often incurable diseases characterized by multiple recurrences and relapses¹



Response and remission duration decline with subsequent treatments, and cumulative toxicities increase^{3,4}


Continued need for active, well-tolerated treatment options for R/R MZL & FL



a=FL: 12,000 treated; MZL: 6,000 treated; b= FL: 5,000 treated, MZL: 2,500 treated; c=FL: 2,500 treated, MZL: 1,000 treated. (expect FDA approval in 2L+ MZL and 3L+FL) (1) Denlinger NM, et al. Cancer Manage Res 2018; Rivas-Delgado A, et al. Brit J Haematology 2019; (2) Putnam Associates, 2018; (3) Putnam Associates, 2019; (4) Kritharis A, et al. Cancer Treatment and Research, 2015; 5. Morrison V, et al. Clin Lymphoma, Myeloma, and Leukemia. 2019]

Ublituximab:

Investigational Next Generation Anti-CD20 Monoclonal Antibody



Ublituximab

Glycoengineered for enhanced potency over 1st generation

Activity in rituximab refractory patients

Shorter infusion time than approved anti-CD20s




UNITY-CLL Phase 3 Trial of U2 in CLL



POSITIVE TOPLINE RESULTS – MAY 2020

- **UNITY-CLL** met the primary endpoint of improved PFS (p<.0001)
- Trial will be stopped early for superior efficacy observed at the interim analysis
- PFS benefit seen across both treatment naïve & relapsed/refractory patient populations
- Full data presentation and regulatory submission targeted by year-end 2020/early 2021





Assessment

10

CLL Market Opportunity

One of the Fastest Growing Global Hematology Markets

- ~115,000 Americans living with CLL
- ~20,000 newly-diagnosed patients each year
- ~20,000 previously treated patients seeking treatment each year



U2 Has the Potential to Address Unmet Needs in CLL

- **Over 60,000 patients** in the US have been treated with a BTK-inhibitor creating a large population in the post-BTK setting in need of treatment options
- ~20% of treatment naïve patients will be deemed poor candidates for BTK inhibitors due to potential safety/tolerability concerns
- **Up to 40% of patients will discontinue** BTK inhibitors for efficacy/tolerability issues at median of 17 months from starting therapy in recent real-world analysis
- Venetoclax represents a challenge for community practices due to enhanced monitoring and potential need for hospitalization to avoid TLS

> Substantial need for additional treatments for CLL remains




U2-Based Triplets Currently Enrolling

U2 + Venetoclax		U2 + Ibrutinib		U2 + 1701 (BTKi)	
		Phase 1 Study in rel/ref B-cell malignances		Phase 1 Study in rel/ref B-cell malignances	
Target Enrollment: Rel/Ref CLL BTK Refractory CLL Front line CLL Completion	~60 patients ~30 patients ~60 patients Q1 2021	Enrolled:	~50 patients	Target Enrollment:	Up to 100 patients
		Published:	Lancet Oncology, Jan. 2019	Target Determination of Ph 3 Dose:	Q4 2020
Primary Endpoint(s):	ORR and CR @ 12 months	Primary Endpoint(s)	Safety, Efficacy	Primary Endpoint(s)	Safety
Phase 1 U2+Ven ASH `19 Update (Barr et al)	CLL Patients: ORR= 100% (n=9) CR= 44% PB MRD-= 100% BM MRD-= 78%	Lancet Jan 2019 (Nastoupil et al)	CLL/SLL Patients: ORR= 100% (n=22) CR= 36% (8/22) MZL Patients: ORR= 100% (3/3)	EHA '20 Update (Cheah et al)	Triple U2 +1701: All Patients ORR= 77% (n=13) CLL ORR= 100% (3/3) MZL ORR= 100% (2/2) Single Agent 200mg:
					CLL ORR= 92% (11/12)

Ublituximab in Relapsing Forms of Multiple Sclerosis


- ~1M Americans living with MS
- Completed Phase 2, data presented at multiple conferences
- Fully Enrolled Phase 3
 ULTIMATE Trials
 - Special Protocol Assessment (SPA)
 - Topline Data Targeted for Q4 2020





Final Ublituximab Phase 2 Data in RMS

- Ublituximab was well tolerated across all patients (n=48)
- No study drug related discontinuations occurred
- Median B cell depletion was >99% at the primary analysis point of Week 4 (n=48) and maintained at Week 24 and Week 48
- No T1 Gd-enhancing lesions were detected in any subjects at Week 24 or Week 48 (100% reduction; p=0.003)
- An Annualized Relapse Rate (ARR) of 0.07 was observed with 93% of subjects relapse free at Week 48



Subject T1 Gd MRI at Baseline, Week 24 & Week 48





Fox E et al., ECTRIMS 2018



Significant Opportunity for Ublituximab in MS

Global MS Market 2018 - 2025

Billions US US Ex-US (Japan, France, Germany, Italy, Spain & UK)

Estimated Global Sales


Global Prevalence = ~2.3Million

Global Market Size >\$30Billion by 2025

• Ocrelizumab >\$2 Billion in 2018 annual sales; achieved ~\$4B in 2019



Multiple Treatment Options Coexist & Account for Meaningful Market Share



TG Therapeutics

17

Ublituximab Potential Value Proposition in MS

- Significant activity and manageable safety profile in Phase 2 study
- Convenience of 1 hour infusion every 6 months v. 3-4 hours for ocrelizumab
- Potential to strategically price to optimize patient access
- Estimate \$1-2B annual market opportunity in the US alone for ublituximab in MS



Target Milestones

1H 2020

Report topline UNITY-NHL FL results

Initiate rolling NDA submission for umbralisib to treat relapsed/refractory MZL & FL

Report topline UNITY-CLL results

Present updated data at major medical meetings

Complete NDA submission for umbralisib to treat relapsed/refractory MZL & FL

2H 2020 – Q1 2021

NDA submission for umbralisib to treat MZL & FL accepted by US FDA & PDUFA goal dates set

- Report topline Phase 3 ULTIMATE MS data
- Present final data from UNITY-CLL & UNITY-NHL umbralisib monotherapy MZL & FL cohorts
- Submit NDA/BLA for U2 to treat CLL
- Complete enrollment in ULTRA-V Phase 2b trial



Key Financial Statistics

